Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy

dc.contributor.authorFung, Chunkit
dc.contributor.authorSesso, Howard D.
dc.contributor.authorWilliams, Annalynn M.
dc.contributor.authorKerns, Sarah L.
dc.contributor.authorMonahan, Patrick
dc.contributor.authorAbu Zaid, Mohammad
dc.contributor.authorFeldman, Darren R.
dc.contributor.authorHamilton, Robert J.
dc.contributor.authorVaughn, David J.
dc.contributor.authorBeard, Clair J.
dc.contributor.authorKollmannsberger, Christian K.
dc.contributor.authorCook, Ryan
dc.contributor.authorAlthouse, Sandra
dc.contributor.authorArdeshir-Rouhani-Fard, Shirin
dc.contributor.authorLipshultz, Steve E.
dc.contributor.authorEinhorn, Lawrence H.
dc.contributor.authorFossa, Sophie D.
dc.contributor.authorTravis, Lois B.
dc.contributor.departmentDepartment of Medicine, IU School of Medicineen_US
dc.date.accessioned2017-07-07T19:41:40Z
dc.date.available2017-07-07T19:41:40Z
dc.date.issued2017-04
dc.description.abstractPurpose To provide new information on adverse health outcomes (AHOs) in testicular cancer survivors (TCSs) after four cycles of etoposide and cisplatin (EPX4) or three or four cycles of bleomycin, etoposide, cisplatin (BEPX3/BEPX4). Methods Nine hundred fifty-two TCSs > 1 year postchemotherapy underwent physical examination and completed a questionnaire. Multinomial logistic regression estimated AHOs odds ratios (ORs) in relation to age, cumulative cisplatin and/or bleomycin dose, time since chemotherapy, sociodemographic factors, and health behaviors. Results Median age at evaluation was 37 years; median time since chemotherapy was 4.3 years. Chemotherapy consisted largely of BEPX3 (38.2%), EPX4 (30.9%), and BEPX4 (17.9%). None, one to two, three to four, or five or more AHOs were reported by 20.4%, 42.0%, 25.1%, and 12.5% of TCSs, respectively. Median number after EPX4 or BEPX3 was two (range, zero to nine and zero to 11, respectively; P > .05) and two (range, zero to 10) after BEPX4. When comparing individual AHOs for EPX4 versus BEPX3, Raynaud phenomenon (11.6% v 21.4%; P < .01), peripheral neuropathy (29.2% v 21.4%; P = .02), and obesity (25.5% v 33.0%; P = .04) differed. Larger cumulative bleomycin doses (OR, 1.44 per 90,000 IU) were significantly associated with five or more AHOs. Increasing age was a significant risk factor for one to two, three to four, or five or more AHOs versus zero AHOs (OR, 1.22, 1.50, and 1.87 per 5 years, respectively; P < .01); vigorous physical activity was protective (OR, 0.62, 0.51, and 0.41, respectively; P < .05). Significant risk factors for three to four and five or more AHOs included current (OR, 3.05 and 3.73) or former (OR, 1.61 and 1.76) smoking (P < .05). Self-reported health was excellent/very good in 59.9% of TCSs but decreased as AHOs increased (P < .001). Conclusion Numbers of AHOs after EPX4 or BEPX3 appear similar, with median follow-up of 4.3 years. A healthy lifestyle was associated with reduced number of AHOs.en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.citationFung, C., Sesso, H. D., Williams, A. M., Kerns, S. L., Monahan, P., Abu Zaid, M., ... & Kollmannsberger, C. K. (2017). Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy. Journal of Clinical Oncology, 35(11), 1211-1222. http://doi.org/10.1200/JCO.2016.70.3108en_US
dc.identifier.urihttps://hdl.handle.net/1805/13350
dc.language.isoenen_US
dc.publisherAmerican Society of Clinical Oncologyen_US
dc.relation.isversionof10.1200/JCO.2016.70.3108en_US
dc.relation.journalJournal of Clinical Oncologyen_US
dc.rightsPublisher Policyen_US
dc.sourcePublisheren_US
dc.subjectadverse health outcomesen_US
dc.subjecttesticular canceren_US
dc.subjectCisplatin-based chemotherapyen_US
dc.titleMulti-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapyen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Fung_2017_multi-institutional.pdf
Size:
670.68 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.88 KB
Format:
Item-specific license agreed upon to submission
Description: